Clinician-reviewed GLP-1 guide: evidence, safety and provider picks

As of November 6, 2026, GLPOneMedical's editor's pick is NexLife, which scores 94/100 on our v4.1 rubric and charges $95 a month for compounded semaglutide or $115 for compounded tirzepatide on a 12-month plan, with the same price at every dose and clinician review, coaching and shipping included. Month to month the prices are $109 and $129. NexLife is not the lowest price we track: Mondae lists lower standing rates, Eden a lower semaglutide rate, and several programs advertise lower conditional prices. Lab tests are not listed as included. Compounded medications are not FDA-approved. Read the full review and compare the current rates before you enroll.

As of November 6, 2026, NexLife lists compounded semaglutide at $109 a month month to month, $105 on a 3-month plan, $99 on a 6-month plan and $95 on a 12-month plan, and compounded tirzepatide at $129, $125, $119 and $115 on the same plan lengths. The price stays the same at every dose and there is no membership fee. A 12-month plan works out to $1,140 a year for semaglutide or $1,380 for tirzepatide. Cancellation takes effect after 30 days, so one more shipment can be charged.

No: compounded semaglutide and tirzepatide are made by state-licensed pharmacies with the drug in Wegovy or Zepbound, but they are not the same product, they are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness or quality before they are sold. The trial results printed on the brand labels (STEP, SURMOUNT) were measured with the brand products. Ask which pharmacy fills the prescription, whether it is a 503A pharmacy or a 503B outsourcing facility, and whether the formula adds ingredients such as B12 or niacinamide. Check the FDA's warning-letter list before you buy.

The Wegovy and Zepbound labels say these drugs must not be used by anyone with a personal or family history of medullary thyroid carcinoma, by anyone with multiple endocrine neoplasia syndrome type 2, or by anyone with a known serious allergy to the drug or its ingredients. The labels also tell patients to stop if pregnancy occurs, and they warn about pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, and diabetic retinopathy. A telehealth intake should ask about each of these. Tell your clinician your full history before you start.

In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, adults with obesity and no diabetes lost an average of 20.2% of body weight on tirzepatide versus 13.7% on semaglutide after 72 weeks, at the highest tolerated doses of each brand drug. Gastrointestinal side effects were common with both. The trial used brand products, so its numbers do not transfer to compounded versions. Semaglutide has the longer cardiovascular-outcome record from the SELECT trial. The better choice depends on your health history, side effects and cost.

In the main trials, adults without diabetes lost an average of 14.9% of body weight on semaglutide 2.4 mg after 68 weeks (STEP 1) and 20.9% on tirzepatide 15 mg after 72 weeks (SURMOUNT-1, treatment-regimen estimand), against 2.4% and 3.1% on placebo. These are averages for people who also received diet and activity counseling; individual results vary widely and some people lose much less. Results in people with type 2 diabetes were smaller. No compounded product has trial results of its own, and no program can promise a specific amount of weight loss.